

Special Issue

Recent Advances in Techniques with Radionuclide for Theranostic Drugs

Message from the Guest Editors

In recent years, theranostics (a word coined from “therapeutics” and “diagnostics”) have attracted much attention in oncology. A typical theranostic system has an imaging component for investigating a lesion site before treatment and a corresponding therapeutic one. Because the diagnosis makes the selection of suitable treatment and dose adjustment for each patient possible, theranostics can contribute to the realization of personalized medicine. Theranostics combined with a diagnostic and a therapeutic radionuclide is called “radiotheranostics.” This Special Issue will focus on the synthesis and/or evaluation of radiolabeled compounds containing dosimetry for their clinical application, radionuclide production and separation, and combination of a radionuclide with other modalities for not only radiotheranostics but also imaging as companion diagnosis. You are cordially invited to contribute to this Special Issue “Recent Advances in Techniques with Radionuclide for Theranostic Drugs” with original articles, as well as reviews and short communications.

Guest Editors


Prof. Dr. Kazuma Ogawa

Dr. Shigeki Watanabe

Dr. Ryuichi Nishii

Deadline for manuscript submissions

closed (15 December 2021)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed




mdpi.com/si/60894

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 29th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).